The publisher of RxforAmericanHealth, a
website dedicated to lowering prescription medicine prices for Americans by the
use of personal importation of safe, affordable brand-name medicines says that
the recently leaked disclosures of the tactics and goals of Pharma in the
secret meetings of the Trans-Pacific Partnership calls for a Congressional
investigation into the “totality of Pharma relationships to influence U.S. health
care policy to its advantage free of public input”.
In his statement, Daniel Hines, who
also publishes TodaysSeniorsNetwork and is preparing the launch of An American Rxbill
of Rights site, noted:
“The leak from the Trans-Pacific Agreement is
irrefutable evidence that Pharma is engaged in a series of actions in the US
and Internationally to manipulate, ensure and protect its predatory pricing
practices in the US, which represents a ‘safe haven’ for it to impose the
highest prescription medicines in the world upon Americans, and to impose them
upon a global scale.
“That Pharma engages in behind-closed-doors
arrangements with this Administration
and Congress to implement its strategies has been evidenced for years with exorbitant
campaign contributions to elected officials, and its often-times ‘too cozy’ relationship
with the Food and Drug Administration.
“Now we see that Pharma has no limits within its
sites. Not content with ‘pay to delay’, questionable patent extensions for designer
medicines, or the potential of abusive seizures and possible destruction of
safe, valid personally imported prescription medicines that are vital and affordable
lifelines for millions of Americans, Pharma has set out to disrupt the
authority of US policy-makers even more to the extent of further endangering
the health and well-being of untold numbers of Americans by dictating
procedures that would weaken the effectiveness of Medicare programs on which so
many Americans rely and trust.
“For that reason, and, in the sake of
transparency, it is imperative that there be a public awareness that will be
best created by a Congressional investigation into the totality of the
relationships of Pharma with policy-makers in the US.
“The House of Representatives is nearing a vote on
whether the interests of Americans will be served with a vote denying
fast-track authority, or, by passage, allowing Pharma to resurrect its goals free
of any opportunity for oversight.
“The vote will be carefully monitored, and I am
confident that advocacy and public interest groups will spare no effort to
ensure that Americans are aware of the outcome, urging them to let their Representatives know
where they stand, and that any support of lack of transparency and
accountability to the American public will not be acceptable in 2016.”
No comments:
Post a Comment